Press Releases

Filter Releases

Date	Title and Summary	View
Toggle SummarySep 02, 2015	Onconova Therapeutics, Inc. to Present Corporate Update at Rodman & Renshaw 17th Annual Global Investment Conference NEWTOWN, Pa., Sept. 02, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and Chief Executive Officer, will present	View HTML Onconova Therapeutics, Inc. to Present Corporate Update at Rodman & Renshaw 17th Annual Global Investment Conference 14.3 KB
Toggle SummaryAug 27, 2015	Onconova Therapeutics Files European Clinical Trial Applications for Global Phase 3 Trial for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes Trial Expected to Begin in Second Half of 2015	View HTML Onconova Therapeutics Files European Clinical Trial Applications for Global Phase 3 Trial for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes 16.9 KB
Toggle SummaryAug 13, 2015	Onconova Therapeutics Announces Submission of Investigational New Drug Application for Pivotal Phase 3 Trial for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes Key Milestone in Positioning Rigosertib on Approval Track for HR-MDS Pivotal Phase 3 Trial Expected to Begin in Second Half of 2015 NEWTOWN, Pa., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and	View HTML Onconova Therapeutics Announces Submission of Investigational New Drug Application for Pivotal Phase 3 Trial for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes 15.9 KB
Toggle SummaryAug 13, 2015	Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2015 Financial Results NEWTOWN, Pa., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the three and six months	View HTML Onconova Therapeutics Inc. Reports Recent Business Highlights and Second Quarter 2015 Financial Results.pdf 253.6 KB
Toggle SummaryJul 08, 2015	Onconova Appoints James J. Marino, Esq. to Board of Directors	View HTML Onconova Appoints James J. Marino, Esq. to Board of Directors 15.9 KB
Toggle SummaryJul 01, 2015	Onconova Therapeutics, Inc. to Present Corporate Update at the Cantor Fitzgerald Healthcare Conference	View HTML Onconova Therapeutics, Inc. to Present Corporate Update at the Cantor Fitzgerald Healthcare Conference 15 KB
Toggle SummaryJun 23, 2015	Onconova to Host Myelodysplastic Syndromes (MDS) Key Opinion Leader Meeting on Tuesday, June 30 in New York City	View HTML Onconova to Host Myelodysplastic Syndromes (MDS) Key Opinion Leader Meeting on Tuesday, June 30 in New York City 17.4 KB
Toggle SummaryJun 15, 2015	Onconova Presents Patient Selection Criteria and Intermediate Clinical Endpoints for Rigosertib in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at EHA Annual Meeting Data Support Planned Phase 3 Pivotal Trial in HR-MDS	View HTML Onconova Presents Patient Selection Criteria and Intermediate Clinical Endpoints for Rigosertib in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at EHA Annual Meeting 18.1 KB
Toggle SummaryJun 01, 2015	Onconova Presents Clinical Data on Rigosertib in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at the 2015 ASCO Annual Meeting Data Support Planned Phase 3 Pivotal Trial in HR-MDS	View HTML Onconova Presents Clinical Data on Rigosertib in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at the 2015 ASCO Annual Meeting 19.6 KB
Toggle SummaryMay 14, 2015	Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2015 Financial Results	View HTML Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2015 Financial Results 27.6 KB
Toggle SummaryMay 13, 2015	Onconova Announces Multiple Rigosertib Clinical Data Presentations at the 2015 ASCO Annual Meeting Data Regarding Prognostic Factors and Intermediate Clinical Endpoints for Rigosertib in Higher-Risk MDS (HR-MDS)	View HTML Onconova Announces Multiple Rigosertib Clinical Data Presentations at the 2015 ASCO Annual Meeting 18.1 KB
Toggle SummaryMay 01, 2015	Onconova Presenting Nine Abstracts Related to Rigosertib at the 13th International Symposium on Myelodysplastic Syndromes (MDS) Updated Data From Multiple Clinical Trials of Rigosertib in MDS	View HTML Onconova Presenting Nine Abstracts Related to Rigosertib at the 13th International Symposium on Myelodysplastic Syndromes (MDS) 22.2 KB
Toggle SummaryApr 21, 2015	Onconova Therapeutics, Inc. Highlights Rigosertib and Early-stage Programs at the 2015 American Association of Cancer Research (AACR) Annual Meeting	View HTML Onconova Therapeutics, Inc. Highlights Rigosertib and Early-stage Programs at the 2015 American Association of Cancer Research (AACR) Annual Meeting 19.9 KB
Toggle SummaryApr 20, 2015	Onconova Therapeutics, Inc. Submits Pivotal Clinical Trial Protocol for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes to FDA and EMA	View HTML Onconova Therapeutics, Inc. Submits Pivotal Clinical Trial Protocol for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes to FDA and EMA 16.6 KB
Toggle SummaryApr 07, 2015	Onconova Therapeutics, Inc. to Present New Data on Rigosertib and Earlier-Stage Programs at the 2015 American Association of Cancer Research (AACR) Annual Meeting Depth of Company's Clinical and Pre-Clinical Pipeline Highlighted	View HTML Onconova Therapeutics, Inc. to Present New Data on Rigosertib and Earlier-Stage Programs at the 2015 American Association of Cancer Research (AACR) Annual Meeting 17.2 KB